Connect with us
MARE BALTICUM Gaming & TECH Summit 2024

Artificial Intelligence

Lantheus Reports Second Quarter 2022 Financial Results

Published

2 years ago

on

  • Worldwide revenue of $223.7 million for the second quarter 2022, representing an increase of 121.4% from the prior year period
  • GAAP net income of $43.1 million for the second quarter 2022, compared to GAAP net loss of $26.7 million in the prior year period
  • GAAP fully diluted net income per share of $0.61 for the second quarter 2022, compared to GAAP fully diluted net loss per share of $0.39 in the prior year period; adjusted fully diluted net income per share of $0.89 for the second quarter 2022, compared to adjusted fully diluted net income per share of $0.11 in the prior year period
  • Net cash provided by operating activities was $72.6 million for the second quarter 2022. Free cash flow was $68.3 million in the second quarter 2022
  • The Company provides third quarter 2022 revenue and adjusted diluted earnings per share guidance; increases full year guidance

NORTH BILLERICA, Mass., Aug. 04, 2022 (GLOBE NEWSWIRE) — Lantheus Holdings, Inc. (NASDAQ: LNTH) (Lantheus), a company committed to improving patient outcomes through diagnostics, radiotherapeutics and artificial intelligence solutions that enable clinicians to Find, Fight and Follow disease, today reported financial results for its second quarter ended June 30, 2022.

The Company’s worldwide revenue for the second quarter of 2022 totaled $223.7 million, compared with $101.1 million for the second quarter of 2021, representing an increase of 121.4% from the prior year period.

The Company’s second quarter 2022 GAAP net income was $43.1 million, or $0.61 per fully diluted share, as compared to GAAP net loss of $26.7 million, or $0.39 per fully diluted share for the second quarter of 2021.

The Company’s second quarter 2022 adjusted fully diluted earnings per share were $0.89, as compared to $0.11 for the second quarter of 2021, representing an increase of approximately $0.78 from the prior year period.

Lastly, net cash provided by operating activities was $72.6 million for the second quarter 2022. Free Cash Flow was $68.3 million in the second quarter of 2022, representing an increase of approximately $45.0 million from the prior year period.

“Our record-setting financial results for the first half of 2022 reflect the strength of our strategy and our ability to drive long-term growth,” said Mary Anne Heino, President and CEO. “PYLARIFY, which is firmly established as the PSMA PET imaging agent of choice, continues to propel our growth and have a positive impact on the U.S. prostate cancer community. We continue to be driven by our purpose to Find, Fight and Follow disease to improve patient outcomes and provide sustainable value for shareholders.”

The Company updates its guidance for full year 2022 and offers the following guidance for the third quarter:

    Q3 Guidance Issued August 4, 2022   Previous Guidance Issued April 29, 2022
Q3 FY 2022 Revenue   $220 million – $230 million   N/A
Q3 FY 2022 Adjusted Fully Diluted EPS   $0.80 – $0.85   N/A
    FY Guidance Updated August 4, 2022   FY Guidance Issued April 29, 2022
FY 2022 Revenue   $885 million – $905 million   $800 million – $835 million
FY 2022 Adjusted Fully Diluted EPS   $3.50 – $3.60   $2.90 – $3.15

On a forward-looking basis, the Company does not provide GAAP income per common share guidance or a reconciliation of adjusted fully diluted EPS to GAAP income per common share because the Company is unable to predict with reasonable certainty business development and acquisition related expenses, purchase accounting fair value adjustments (including liability accruals relating to the contingent value rights issued as part of the Progenics Pharmaceuticals, Inc. acquisition), and any one-time, non-recurring charges. These items are uncertain, depend on various factors, and could be material to results computed in accordance with GAAP. As a result, it is the Company’s view that a quantitative reconciliation of adjusted fully diluted EPS on a forward-looking basis is not available without unreasonable effort.

Internet Posting of Information

The Company routinely posts information that may be important to investors in the “Investors” section of its website at www.lantheus.com. The Company encourages investors and potential investors to consult its website regularly for important information about the Company.

Conference Call and Webcast

As previously announced, the Company will host a conference call and webcast on Thursday, August 4, 2022, at 8:00 a.m. ET. To access the conference call or webcast, participants should register online at https://investor.lantheus.com/news-events/calendar-of-events. 

A replay will be available approximately two hours after completion of the webcast and will be archived on the same web page for at least 30 days.

The conference call will include a discussion of non-GAAP financial measures. Reference is made to the most directly comparable GAAP financial measures, the reconciliation of the differences between the two financial measures, and the other information included in this press release, our Form 8-K filed with the SEC today, or otherwise available in the Investor Relations section of our website located at www.lantheus.com. 

The conference call may include forward-looking statements. See the cautionary information about forward-looking statements in the safe-harbor section of this press release.

About Lantheus Holdings, Inc.

With more than 60 years of experience in delivering life-changing science, Lantheus is committed to improving patient outcomes through diagnostics, radiotherapeutics and artificial intelligence solutions that enable clinicians to Find, Fight and Follow disease. Lantheus is headquartered in Massachusetts and has offices in New Jersey, Canada and Sweden. For more information, visit www.lantheus.com. 

Non-GAAP Financial Measures

The Company uses non-GAAP financial measures, such as adjusted net income and its line components; adjusted net income per share – fully diluted; and free cash flow. The Company’s management believes that the presentation of these measures provides useful information to investors. These measures may assist investors in evaluating the Company’s operations, period over period. However, these measures may exclude items that may be highly variable, difficult to predict and of a size that could have a substantial impact on the Company’s reported results of operations for a particular period. Management uses these and other non-GAAP measures internally for evaluation of the performance of the business, including the allocation of resources and the evaluation of results relative to employee performance compensation targets. Investors should consider these non-GAAP measures only as a supplement to, not as a substitute for or as superior to, measures of financial performance prepared in accordance with GAAP.

Safe Harbor for Forward-Looking and Cautionary Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, that are subject to risks and uncertainties and are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements may be identified by their use of terms such as “believe,” “could,” “estimate,” “expect,” “look forward to,” “may,” “plan,” “predict,” “target,” “will,” and other similar terms. Such forward-looking statements are based upon current plans, estimates and expectations that are subject to risks and uncertainties that could cause actual results to materially differ from those described in the forward-looking statements. The inclusion of forward-looking statements should not be regarded as a representation that such plans, estimates and expectations will be achieved. Readers are cautioned not to place undue reliance on the forward-looking statements contained herein, which speak only as of the date hereof. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law. Risks and uncertainties that could cause our actual results to materially differ from those described in the forward-looking statements include: (i) our ability to continue to grow PYLARIFY as a commercial product, including (A) our ability to obtain FDA approval for additional positron emission tomography (“PET”) manufacturing facilities (“PMFs”) to manufacture PYLARIFY, (B) the ability of PMFs to manufacture PYLARIFY to meet product demand, (C) our ability to sell PYLARIFY to customers, (D) our ability to obtain and maintain adequate coding, coverage and payment for PYLARIFY, and (E) our ability to establish PYLARIFY as a leading PSMA PET imaging agent in a competitive environment in which other PSMA PET imaging agents have been approved and additional ones are in development; (ii) continued market expansion and penetration for our established commercial products, particularly DEFINITY, in the face of segment competition and potential generic competition, including as a result of patent and regulatory exclusivity expirations and challenges; (iii) the global Molybdenum-99 (“Mo-99”) supply; (iv) our ability to have third party manufacturers manufacture our products and our ability to use our in-house manufacturing capacity; (v) our ability to successfully launch PYLARIFY AI as a commercial product; (vi) the continuing impact of the global COVID-19 pandemic on our business, supply chain, financial condition and prospects; (vii) the efforts and timing for clinical development and regulatory approval of our product candidates and new clinical applications and territories for our products, in each case, that we may develop, including 1095 and NM-01, or that our strategic partners may develop, including piflufolastat F 18 in Europe and flurpiridaz fluorine-18 (“F 18”); (viii) our ability to identify and acquire or in-license additional diagnostic and therapeutic product opportunities in oncology and other strategic areas; (ix) the potential reclassification by the FDA of certain of our products and product candidates from drugs to devices with the expense, complexity and potentially more limited competitive protection such reclassification could cause; and (x) the risk and uncertainties discussed in our filings with the Securities and Exchange Commission (including those described in the Risk Factors section in our Annual Reports on Form 10-K and our Quarterly Reports on Form 10-Q).

Lantheus Holdings, Inc.
Consolidated Statements of Operations
(in thousands, except per share data – unaudited)

    Three Months Ended
June 30,		   Six Months Ended
June 30,
      2022       2021       2022       2021  
Revenues   $ 223,723     $ 101,064     $ 432,603     $ 193,573  
Cost of goods sold     85,694       54,976       165,504       106,455  
Gross profit     138,029       46,088       267,099       87,118  
Operating expenses                
Sales and marketing     27,492       17,631       47,846       31,804  
General and administrative     32,598       43,177       70,186       59,315  
Research and development     14,735       12,061       26,938       22,421  
Total operating expenses     74,825       72,869       144,970       113,540  
Gain on sale of assets     —       —       —       15,263  
Operating income (loss)     63,204       (26,781 )     122,129       (11,159 )
Interest expense     1,469       1,937       2,978       4,655  
Gain on extinguishment of debt     —       —       —       (889 )
Other income     (310 )     (182 )     (795 )     (731 )
Income (loss) before income taxes     62,045       (28,536 )     119,946       (14,194 )
Income tax expense (benefit)     18,987       (1,879 )     33,926       3,455  
Net income (loss)   $ 43,058     $ (26,657 )   $ 86,020     $ (17,649 )
Net income (loss) per common share:                
Basic   $ 0.63     $ (0.39 )   $ 1.26     $ (0.26 )
Diluted   $ 0.61     $ (0.39 )   $ 1.22     $ (0.26 )
Weighted-average common shares outstanding:                
Basic     68,674       67,505       68,343       67,300  
Diluted     70,796       67,505       70,412       67,300  

Lantheus Holdings, Inc.
Consolidated Revenues Analysis
(in thousands – unaudited)

    Three Months Ended
June 30,		   Six Months Ended
June 30,
    2022 2021 % Change   2022 2021 % Change
DEFINITY   $ 62,306   $ 59,842   4.1 %   $ 120,634   $ 115,813   4.2 %
TechneLite     19,440     23,772   (18.2 )%     42,045     46,572   (9.7 )%
Other precision diagnostics     5,363     6,742   (20.5 )%     10,628     13,726   (22.6 )%
Total precision diagnostics     87,109     90,356   (3.6 )%     173,307     176,111   (1.6 )%
PYLARIFY     130,232     273   N/A       223,009     273   N/A  
Other radiopharmaceutical oncology     928     2,539   (63.5 )%     2,255     4,039   (44.2 )%
Total radiopharmaceutical oncology     131,160     2,812   4,564.3 %     225,264     4,312   5124.1 %
Strategic Partnerships and other revenue     5,454     7,896   (30.9 )%     34,032     13,150   158.8 %
Total revenues   $ 223,723   $ 101,064   121.4 %   $ 432,603   $ 193,573   123.5 %

Lantheus Holdings, Inc.
Reconciliation of GAAP to Non-GAAP Financial Measures
(in thousands, except per share data – unaudited)

    Three Months Ended
June 30,		   Six Months Ended
June 30,
      2022       2021       2022       2021  
Net income   $ 43,058     $ (26,657 )   $ 86,020     $ (17,649 )
Stock and incentive plan compensation     7,412       4,588       13,035       7,905  
Amortization of acquired intangible assets     8,306       6,074       16,612       10,759  
Acquired debt fair value adjustment     —       —       —       (307 )
Contingent consideration fair value adjustments     8,500       25,600       26,900       25,900  
Non-recurring severance related fees     —       92       —       528  
Non-recurring fees     348       —       (384 )     —  
Extinguishment of debt     —       —       —       (889 )
Gain on sale of assets     —       —       —       (15,263 )
Strategic collaboration and license costs     500       —       500       —  
Integration costs     —       11       —       30  
Acquisition-related costs     252       767       699       664  
ARO Acceleration and other related costs     209       —       1,800       —  
Other     (124 )     43       5       53  
Income tax effect of non-GAAP adjustments(a)     (5,578 )     (2,731 )     (14,474 )     (648 )
Adjusted net income   $ 62,883     $ 7,787     $ 130,713     $ 11,083  
Adjusted net income, as a percentage of revenues     28.1 %     7.7 %     30.2 %     5.7 %
    Three Months Ended
June 30,		   Six Months Ended
June 30,
      2022       2021       2022       2021  
Net income per share – diluted   $ 0.61     $ (0.39 )   $ 1.22     $ (0.26 )
Stock and incentive plan compensation     0.10       0.07       0.19       0.12  
Amortization of acquired intangible assets     0.12       0.08       0.24       0.16  
Acquired debt fair value adjustment     —       —       —       (0.01 )
Contingent consideration fair value adjustments     0.13       0.37       0.38       0.38  
Non-recurring severance related fees     —       —       —       0.01  
Non-recurring fees     —       —       (0.01 )     —  
Extinguishment of debt     —       —       —       (0.01 )
Gain on sale of assets     —       —       —       (0.23 )
Strategic collaboration and license costs     0.01       —       0.01       —  
Integration costs     —       —       —       —  
Acquisition-related costs     —       0.02       0.01       0.01  
ARO Acceleration and other related costs     0.01       —       0.03       —  
Other     —       —       —       —  
Income tax effect of non-GAAP adjustments(a)     (0.09 )     (0.04 )     (0.21 )     (0.01 )
Adjusted net income per share – diluted   $ 0.89     $ 0.11     $ 1.86     $ 0.16  
Weighted-average common shares outstanding – diluted     70,796       68,705       70,412       68,281  

(a)  The income tax effect of the adjustments between GAAP net loss and non-GAAP adjusted net income takes into account the tax treatment and related tax rate that apply to each adjustment in the applicable tax jurisdiction.

Lantheus Holdings, Inc.
Reconciliation of Free Cash Flow
(in thousands – unaudited)

  Three Months Ended
June 30,		   Six Months Ended
June 30,
    2022       2021       2022       2021  
Net cash provided by operating activities $ 72,597     $ 25,869     $ 82,861     $ 35,687  
Capital expenditures   (4,343 )     (2,656 )     (7,533 )     (5,176 )
Free cash flow $ 68,254     $ 23,213     $ 75,328     $ 30,511  
               
Net cash (used in) provided by investing activities $ (4,343 )   $ (2,656 )   $ (5,733 )   $ 10,647  
Net cash used in financing activities $ (2,011 )   $ (715 )   $ (4,190 )   $ (35,506 )

Lantheus Holdings, Inc.
Condensed Consolidated Balance Sheets
(in thousands – unaudited)

  June 30,
2022		   December 31,
2021
Assets      
Current assets      
Cash and cash equivalents $ 171,427   $ 98,508
Accounts receivable, net   187,051     89,336
Inventory   33,958     35,129
Other current assets   11,986     12,818
Total current assets   404,422     235,791
Property, plant and equipment, net   119,004     116,772
Intangibles, net   331,898     348,510
Goodwill   61,189     61,189
Deferred tax assets, net   55,155     62,764
Other long-term assets   42,156     38,758
Total assets $ 1,013,824   $ 863,784
Liabilities and stockholders’ equity      
Current liabilities      
Current portion of long-term debt and other borrowings $ 14,065   $ 11,642
Accounts payable   21,153     20,787
Accrued expenses and other liabilities   183,798     58,068
Total current liabilities   219,016     90,497
Asset retirement obligations   22,196     20,833
Long-term debt, net and other borrowings   155,664     163,121
Other long-term liabilities   49,616     124,894
Total liabilities   446,492     399,345
Total stockholders’ equity   567,332     464,439
Total liabilities and stockholders’ equity $ 1,013,824   $ 863,784

Contacts:
Mark Kinarney
Vice President, Investor Relations
978-671-8842
[email protected] 

Melissa Downs
Senior Director, Corporate Communications
646-975-2533
[email protected] 

 

Related Topics:

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Continue Reading

Artificial Intelligence

SciBase publishes prospectus in connection with upcoming rights issue

Published

39 mins ago

on

April 19, 2024

By

scibase-publishes-prospectus-in-connection-with-upcoming-rights-issue

STOCKHOLM, April 19, 2024 /PRNewswire/ — On 5 April 2024, SciBase Holding AB (publ) (“SciBase” or the “Company”) announced that the Board of Directors, with the support of the authorization granted by the annual general meeting held on 17 May 2023, had resolved on a rights issue of units, consisting of new shares and warrants of series TO 2, of approximately SEK 15 million (the “Rights Issue). Today, SciBase announces that the prospectus relating to the Rights Issue (the “Prospectus”) has been approved by the Swedish Financial Supervisory Authority (the “SFSA”) and has been made available on the Company’s webpage, https://investors.scibase.se/en/share/prospectus-regarding-shares, together with other information related to the Rights Issue. The Prospectus will also be made available on Vator Securities’ webpage, www.vatorsecurities.se , and at the SFAS’s webpage, www.fi.se.

THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH SUCH ACTIONS, WHOLLY OR IN PART, WOULD BE UNLAWFUL. THIS PRESS RELEASE DOES NOT CONSTITUTE AN OFFER TO BUY SECURITIES IN SCIBASE HOLDING AB (PUBL). SEE ALSO THE SECTION “IMPORTANT INFORMATION” BELOW IN THIS DOCUMENT.
Timetable for the Rights Issue
19 April 2024 
Record date to receive unit rights
23 April 2024 – 2 May 2024 
Trading in unit rights
23 April 2024 – 7 May 2024 
Subscription period           
23 April 2024 – 27 May 2024
Trading in BTU
Around 10 May 2024 
Announcement of the outcome of the Rights Issue
3 April 2029 – 17 April 2029
Subscription period for warrants of series TO 2
Advisors
Vator Securities is the financial advisor and Advokatfirman Schjødt is the legal advisor to SciBase in connection with the Rights Issue.
For additional information, please contact:Pia Renaudin, VD, tel. +46732069802, e-mail: [email protected]
Certified Advisor (CA)Vator SecuritiesTel: +46 8 580 065 99Email: [email protected]
About SciBase
SciBase is a global medical technology company, specializing in early detection and prevention in dermatology. SciBase develops and commercializes Nevisense, a unique point-of-care platform that combines AI (artificial intelligence) and advanced EIS technology to elevate diagnostic accuracy, ensuring proactive skin health management.
Our commitment is to minimize patient suffering, allowing clinicians to improve and save lives through timely detection and intervention and reduce healthcare costs.
Built on more than 20 years of research at Karolinska Institute in Stockholm, Sweden, SciBase is a leader in dermatological advancements.
The Company has been on the Nasdaq First North Growth Market exchange since June 2, 2015. Learn more at www.scibase.com. All press releases and financial reports can be found here: http://investors.scibase.se/en/pressreleases
Important information
Publication, release or distribution of this press release may in certain jurisdictions be subject to legal restrictions and persons in the jurisdictions where this press release has been made public or distributed should be informed of and follow such legal restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with applicable rules in each jurisdiction. This press release does not constitute an offer or solicitation to buy or subscribe for any securities in SciBase in any jurisdiction, either from SciBase or from anyone else.
This press release is not a prospectus according to the definition in Regulation (EU) 2017/1129 (the “Prospectus Regulation”) and has not been approved by any regulatory authority in any jurisdiction. Any acquisition of units in SciBase in the Rights Issue should only be made on the basis of the information contained in the formal prospectus issued in connection with the Rights Issue, which was approved by the Swedish Financial Supervisory Authority on 19 April 2024.
This press release does not constitute an offer or solicitation to buy or subscribe for securities in the United States. The securities mentioned herein may not be sold in the United States without registration, or without an exemption from registration, under the U.S. Securities Act from 1933 (“Securities Act”) and may not be offered or sold within the United States without being registered, covered by an exemption from, or part of a transaction that is not subject to the registration requirements according to the Securities Act. There is no intention to register any securities mentioned herein in the United States or to issue a public offering of such securities in the United States. The information in this press release may not be released, published, copied, reproduced or distributed, directly or indirectly, wholly or in part, in or to Australia, Belarus, Canada, Hong Kong, Japan, New Zealand, Russia, Switzerland, Singapore, South Africa, the United States or any other jurisdiction where the release, publication or distribution of this information would violate current rules or where such an action is subject to legal restrictions or would require additional registration or other measures beyond those that follow from Swedish law. Actions in contravention of this instruction may constitute a violation of applicable securities legislation.
Forward-looking statements
This press release contains forward-looking statements related to the Company’s intentions, estimates or expectations with regard to the Company’s future results, financial position, liquidity, development, outlook, estimated growth, strategies and opportunities as well as the markets in which the Company is active. Forward-looking statements are statements that do not refer to historical facts and can be identified by the use of terms such as “believes,” “expects,” “anticipates,” “intends,” “estimates,” “will,” “may,” “implies,” “should,” “could” and, in each case, their negative, or comparable terminology. The forward-looking statements in this press release are based on various assumptions, which in several cases are based on further assumptions. Although the Company believes that the assumptions reflected in these forward-looking statements are reasonable, there is no guarantee that they will occur or that they are correct. Since these assumptions are based on assumptions or estimates and involve risks and uncertainties, actual results or outcomes, for many different reasons, may differ materially from those what is stated in the forward-looking statements. Due to such risks, uncertainties, eventualities and other significant factors, actual events may differ materially from the expectations that expressly or implicitly are contained in this press release through the forward-looking statements. The Company does not guarantee that the assumptions which serve as a basis for the forward-looking statements in this press release are correct, and each reader of the press release should not rely on the forward-looking statements in this press release. The information, opinions and forward-looking statements that expressly or implicitly are stated herein are provided only as of the date of this press release and may change. Neither the Company nor any other party will review, update, confirm or publicly announce any revision of any forward-looking statement to reflect events that occur or circumstances that arise with respect to the contents of this press release, beyond what is required by law or Nasdaq First North Growth Market Rulebook for Issuers of Shares.
This information was brought to you by Cision http://news.cision.com
https://news.cision.com/scibase/r/scibase-publishes-prospectus-in-connection-with-upcoming-rights-issue,c3964524
The following files are available for download:
https://mb.cision.com/Main/12371/3964524/2745667.pdf
Publishing of prospectus SciBase
 

View original content:https://www.prnewswire.co.uk/news-releases/scibase-publishes-prospectus-in-connection-with-upcoming-rights-issue-302122089.html

Continue Reading

Artificial Intelligence

Clinical Trials Matching Software Market Projected to Reach $832.56 million by 2030 – Exclusive Report by 360iResearch

Published

9 hours ago

on

April 19, 2024

By

clinical-trials-matching-software-market-projected-to-reach-$832.56-million-by-2030-–-exclusive-report-by-360iresearch

PUNE, India, April 18, 2024 /PRNewswire/ — The report titled “Clinical Trials Matching Software Market by Functionality (Analytics & Reporting, Compliance Tracking, Data Management), Deployment (Cloud & Web Based, On-Premise), End-Use – Global Forecast 2024-2030” is now available on 360iResearch.com’s offering, presents an analysis indicating that the market projected to grow from a size of $342.20 million in 2023 to reach $832.56 million by 2030, at a CAGR of 13.54% over the forecast period.

“The Global Surge in Adoption of Matching Software for Enhanced Participant Enrollment”
Clinical trials matching software stands at the forefront of revolutionizing clinical research by automating the process of identifying and enrolling eligible participants. These platforms offer a streamlined approach to match patient health profiles with trial requirements, accelerating enrollment and supporting the shift toward personalized healthcare using these advanced AI and ML technologies. Although integrating these systems poses challenges due to variations in healthcare IT infrastructure and the imperative for rigorous data security, the potential for market growth is substantial. In the Americas, a robust clinical trials ecosystem thrives; in the European Union, it has unified regulatory standards and extended to emerging regions such as the Middle East, Africa, and the APAC countries; the demand for such innovative solutions is on a steep rise. This demand is fueled by governmental support, the evolving regulatory landscape, and strategic partnerships to embed these solutions within electronic health records, underscoring a global movement toward optimizing clinical trial processes to better cater to specific patient demographics.
Download Sample Report @ https://www.360iresearch.com/library/intelligence/clinical-trials-matching-software
“The Rise of Virtual Trials and Advanced Matching Software”
The healthcare landscape is witnessing a transformative shift toward virtual clinical trials, fueled by technological advancements and the necessity for continuity during the COVID-19 pandemic. This transition supports research amid social distancing measures and introduces significant cost savings by reducing the need for physical infrastructure and in-person interactions. The efficiencies brought by electronic health records (EHR), wearable technologies, and automation streamline the entire process, from patient recruitment to data analysis. Several approaches, endorsed by regulatory bodies such as the FDA, represent a leap forward in making clinical trials more accessible and streamlined, ensuring that more patients can participate in potentially life-saving research without the geographical and logistic constraints of traditional trials.
“Enhancing Clinical Trials through Advanced Analytics, Rigorous Compliance, and Precision-Patient Matching”
Integrating advanced analytics, meticulous compliance monitoring, and precision-patient matching marks a significant advancement toward maximizing efficiency and fostering trial diversity. The software delivers insightful data on trial progress, participant demographics, and enrollment figures, empowering stakeholders to make well-informed decisions and optimize resource distribution to meet trial goals effectively by implementing cutting-edge analytics. The built-in compliance feature ensures trials are conducted in strict adherence to regulatory standards, minimizing risks associated with non-compliance. Furthermore, a robust data management system guarantees the integrity and availability of clinical trial data, which is critical for the seamless operation and real-time analysis of trials. The software includes state-of-the-art patient matching technology, which employs sophisticated algorithms and artificial intelligence to expedite recruitment by accurately identifying candidates who match specific trial requirements. This innovative approach accelerates the recruitment timeline and enhances the diversification of trial participants, paving the way for more inclusive and representative clinical research outcomes.
Request Analyst Support @ https://www.360iresearch.com/library/intelligence/clinical-trials-matching-software
“Medidata by Dassault Systèmes SE at the Forefront of Clinical Trials Matching Software Market with a Strong 11.30% Market Share”
The key players in the Clinical Trials Matching Software Market include International Business Machines Corporation, Science 37, Inc. by eMed, LLC, Medidata by Dassault Systèmes SE, AutoCruitment LLC, Deep 6 AI Inc., and others. These prominent players focus on strategies such as expansions, acquisitions, joint ventures, and developing new products to strengthen their market positions.
“Introducing ThinkMi: Revolutionizing Market Intelligence with AI-Powered Insights for the Clinical Trials Matching Software Market”
We proudly unveil ThinkMi, a cutting-edge AI product designed to transform how businesses interact with the Clinical Trials Matching Software Market. ThinkMi stands out as your premier market intelligence partner, delivering unparalleled insights with the power of artificial intelligence. Whether deciphering market trends or offering actionable intelligence, ThinkMi is engineered to provide precise, relevant answers to your most critical business questions. This revolutionary tool is more than just an information source; it’s a strategic asset that empowers your decision-making with up-to-the-minute data, ensuring you stay ahead in the fiercely competitive Clinical Trials Matching Software Market. Embrace the future of market analysis with ThinkMi, where informed decisions lead to remarkable growth.
Ask Question to ThinkMi @ https://app.360iresearch.com/library/intelligence/clinical-trials-matching-software
“Dive into the Clinical Trials Matching Software Market Landscape: Explore 190 Pages of Insights, 286 Tables, and 22 Figures”
PrefaceResearch MethodologyExecutive SummaryMarket OverviewMarket InsightsClinical Trials Matching Software Market, by FunctionalityClinical Trials Matching Software Market, by DeploymentClinical Trials Matching Software Market, by End-UseAmericas Clinical Trials Matching Software MarketAsia-Pacific Clinical Trials Matching Software MarketEurope, Middle East & Africa Clinical Trials Matching Software MarketCompetitive LandscapeCompetitive PortfolioInquire Before Buying @ https://www.360iresearch.com/library/intelligence/clinical-trials-matching-software
Related Reports:
Clinical Trial Support Services Market – Global Forecast 2024-2030Virtual Clinical Trials Market – Global Forecast 2024-2030Clinical Trials Management System Market – Global Forecast 2024-2030About 360iResearch
Founded in 2017, 360iResearch is a market research and business consulting company headquartered in India, with clients and focus markets spanning the globe.
We are a dynamic, nimble company that believes in carving ambitious, purposeful goals and achieving them with the backing of our greatest asset — our people.
Quick on our feet, we have our ear to the ground when it comes to market intelligence and volatility. Our market intelligence is diligent, real-time and tailored to your needs, and arms you with all the insight that empowers strategic decision-making.
Our clientele encompasses about 80% of the Fortune Global 500, and leading consulting and research companies and academic institutions that rely on our expertise in compiling data in niche markets. Our meta-insights are intelligent, impactful and infinite, and translate into actionable data that support your quest for enhanced profitability, tapping into niche markets, and exploring new revenue opportunities.
Contact 360iResearchMr. Ketan Rohom360iResearch Private Limited,Office No. 519, Nyati Empress,Opposite Phoenix Market City,Vimannagar, Pune, Maharashtra,India – 411014.Email: [email protected]: +1-530-264-8485India: +91-922-607-7550
To learn more, visit 360iresearch.com or follow us on LinkedIn, Twitter, and Facebook.
Logo – https://mma.prnewswire.com/media/2359256/360iResearch_Logo.jpg

View original content:https://www.prnewswire.co.uk/news-releases/clinical-trials-matching-software-market-projected-to-reach-832-56-million-by-2030—exclusive-report-by-360iresearch-302119709.html

Continue Reading

Artificial Intelligence

RepTrak Announces 2024 Global RepTrak® 100 Report

Published

17 hours ago

on

April 18, 2024

By

reptrak-announces-2024-global-reptrak-100-report

BOSTON, April 18, 2024 /PRNewswire/ — The RepTrak™ Company, the world’s leading reputation data and insights company, released its annual Global RepTrak 100 report. Utilizing its advanced reputation monitoring software, RepTrak gathered data from more than 243,000 survey responses across 14 major economies to rank the world’s 100 most reputable companies. They share that ranking alongside a full analysis of global corporate reputation trends and corresponding public sentiment in the 2024 report.

After two years of consecutive Reputation Score declines, this year’s Score is back up with an increase from 73.2 in 2023 to 73.8 in 2024. It’s a small increase after 2023’s full one-point drop. However, it’s an encouraging sign that companies have begun to recover from reputation falls driven by many challenges: macroeconomic issues, workplace difficulties, product problems, and corporate responsibility skepticism.
“This year’s report underscores a pivotal shift in the corporate landscape, spotlighting the remarkable adaptability and dedication of the Top 100 companies in responding to the dynamic needs of stakeholders,” states RepTrak CEO Mark Sonders. “The companies featured in our report are not just riding the wave of change; they are the ones steering it, proving that the best approach to business is one that embraces evolution and champions progress.”
RepTrak’s report explores how people thought, felt, and acted toward companies over the past year. Findings include notable increases in Conduct and Citizenship efforts, stakeholders’ rising willingness to invest, culturally resonant brand communications, and ESG Scores that soared despite skepticism around the acronym.
To read the full 2024 Global RepTrak 100 report, please visit: www.reptrak.com/globalreptrak
About RepTrak
The RepTrak™ Company is the world’s leading reputation data and insights company. We help companies by organizing and grading a variety of reputational elements, offering a real-world report card on their corporate reputation. Subscribers to the RepTrak program use our predictive insights to protect business value, improve return on investment, and increase their positive impact on society. RepTrak’s pairing of advanced metrics and dedicated reputation advisors offers clients an actionable analysis of their reputation data, aligning business objectives with stakeholder sentiment across different markets and sectors.
Established in 2004, The RepTrak Company owns the world’s largest reputation benchmarking database, gathering over 1 million company ratings per year used by CEOs, boards, and executives in more than 60 countries worldwide. For more information, please visit: www.reptrak.com
Logo – https://mma.prnewswire.com/media/2391550/RepTrak_Logo_Logo.jpg
Photo – https://mma.prnewswire.com/media/2391551/2024_GRT_Spreads__Instagram_Post.jpg

View original content:https://www.prnewswire.co.uk/news-releases/reptrak-announces-2024-global-reptrak-100-report-302121513.html

Continue Reading

Trending